Recursion Pharmaceuticals, Inc. Class A Common Stock
Here’s whether Recursion Pharmaceuticals, Inc. Class A Common Stock (RXRX) is worth buying in 2026 — based on weekly-updated price trend, RSI momentum, and return vs. the S&P 500. Our current read: Bearish.
Positives: 50-day MA is rising (+1.59% over 10 days); RSI 53 — healthy momentum range. Concerns: trading below the 200-day MA (long-term downtrend); below the 50-day MA (medium-term momentum negative); weak 1-year return of -39.1%; 3-month momentum negative (-7.1%); rising volume on a downtrend (distribution, 1.21x avg). Currently 56.1% off its 52-week high. Score: -3/7.
RXRX is trading below its 200-day MA ($4.18) — a key warning sign the longer-term trend is under pressure. An RSI of 52.9 sits in the neutral zone — momentum is neither stretched nor exhausted. The 1-year return of -39.1% compares to +22.9% for SPY (trailed the market by 61.9%). The current 56.1% drawdown from the 52-week high reflects elevated risk for momentum-based strategies.